Clinical Research
Evidence by design — not by retrofit.
Every Kihealth Labs program is conceived as a clinical study from day one. Our trial network spans nine major academic medical centers across North America and Europe.
Active studies · 2026
9 sites · 9,310 enrolled
Active studies
Prospective, multi-center, IRB-approved.
INTERCEPT-T1DENROLLING
Beta-cell death in pre-clinical Type 1 Diabetes
N 1,840
Sites 7
Phase Pivotal
PANC-DETECTENROLLING
Surveillance cfDNA in high-risk pancreatic cohorts
N 3,210
Sites 12
Phase Validation
MET-STAGEACTIVE
Multi-tissue staging of metabolic disease progression
N 2,400
Sites 9
Phase Analytical
NEURO-CSFENROLLING
Cortical neuron cfDNA in early Alzheimer's
N 740
Sites 4
Phase Discovery
MRD-MULTIACTIVE
Tumor-naive MRD detection across solid tumors
N 1,120
Sites 6
Phase Validation
Scientific data room
The evidence behind InterceptIQ™.
Live · updated weekly|v2026.06
9
Active studies
9,720
Enrolled subjects
43
Investigator sites
IRB
Approved protocols
Study ID
Title
N
Sites
Enrollment
INTERCEPT-T1D
Enrolling
β-cell death in pre-clinical Type 1 Diabetes
Pivotal · prospective · multi-center
1,840
7
78%1,435/1,840
PANC-DETECT
Enrolling
Surveillance cfDNA in high-risk pancreatic cohorts
Validation · prospective · multi-center
3,210
12
64%2,054/3,210
MET-STAGE
Active
Multi-tissue staging of metabolic disease
Analytical · prospective · multi-center
2,400
9
92%2,208/2,400
NEURO-CSF
Enrolling
Cortical neuron cfDNA in early Alzheimer's
Discovery · prospective · multi-center
740
4
31%229/740
MRD-MULTI
Active
Tumor-naive MRD across solid tumors
Validation · prospective · multi-center
1,120
6
58%650/1,120
INTERCEPT-RX-01
Enrolling
Pharmacodynamic readout, IO combinations
Pharma · prospective · multi-center
410
5
44%180/410
Selected disclosures. Full data package available under NDA. Contact partnerships@kihealth.com.